--- title: "Nanjing Vishee Medical Technology Co., Ltd. (688580.SH)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/688580.SH.md" symbol: "688580.SH" name: "Nanjing Vishee Medical Technology Co., Ltd." industry: "Health Care Equipment" datetime: "2026-05-20T00:19:33.739Z" locales: - [en](https://longbridge.com/en/quote/688580.SH.md) - [zh-CN](https://longbridge.com/zh-CN/quote/688580.SH.md) - [zh-HK](https://longbridge.com/zh-HK/quote/688580.SH.md) --- # Nanjing Vishee Medical Technology Co., Ltd. (688580.SH) ## Company Overview Nanjing Vishee Medical Technology Co., Ltd provides rehabilitation meditation products and solutions in China and internationally. The company offers MagNeuro, a transcranial magnetic stimulation (TMS) for use in anxiety disorders, movement disorders, and ADHD applications; MagNeuro ONE, a TMS therapy system with navigation for use in anxiety disorders applications; and MagBelle, a pelvic floor muscle stimulator for use in urinary incontinence, pelvic organ prolapse, chronic pelvic pain, vaginal laxity, and bowel dysfunction applications. It also provides MagGraver, a powered muscle stimulator for use in abdominal sculpting and body sculpting applications; RFIntima, a radiofrequency therapy product for use in pelvic floor dysfunction, genitourinary syndrome of menopause, and vulvar atrophy applications; and PicoV, a Nd:YAG picosecond laser system for use in pigmentary diseases, and tattoo removal and skin reconstruction applications. In addition, the company offers solutions to pelvic floor and postpartum rehabilitation, rehabilitation medicine, psychiatry, pediatric rehabilitation, and aesthetic medicine. | Item | Detail | |------|--------| | Industry | Health Care Equipment | | Exchange | CN Market | | Website | [www.vishee.com](https://www.vishee.com) | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: B > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-05-19T04:30:10.000Z **Overall: B (0.36)** **Industry**: Health Care Equipment | Metric | Value | |--------|-------| | Industry Ranking | 19 / 64 | | Industry Median | C | | Industry Average | C | - **Style**: Blend - Stocks in which the company has both growth and mature businesses. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **Multi Score**: B #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 15.81% | | | Net Profit YoY | 45.44% | | | P/B Ratio | 3.34 | | | Dividend Ratio | 1.31% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 5850821892.77 | | | Revenue | 472401786.03 | | #### Multi Score Score: B | Indicator | Value | Rating | |-----------|-------|--------| | ROE | 9.66% | B | | Profit Margin | 34.89% | A | | Gross Margin | 66.16% | A | | Revenue YoY | 15.81% | B | | Net Profit YoY | 45.44% | B | | Total Assets YoY | 2.59% | C | | Net Assets YoY | 5.62% | C | | Cash Flow Margin | 0.00% | D | | OCF YoY | 15.81% | B | | Turnover | 0.26 | D | | Gearing Ratio | 5.77% | A | ```chart-data:radar { "title": "Longbridge Financial Score - Nanjing Vishee Medical Technology Co., Ltd.", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "15.81%", "rating": "" }, { "name": "Net Profit YoY", "value": "45.44%", "rating": "" }, { "name": "P/B Ratio", "value": "3.34", "rating": "" }, { "name": "Dividend Ratio", "value": "1.31%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "5850821892.77", "rating": "" }, { "name": "Revenue", "value": "472401786.03", "rating": "" } ] }, { "name": "Multi Score", "grade": "B", "indicators": [ { "name": "ROE", "value": "9.66%", "rating": "B" }, { "name": "Profit Margin", "value": "34.89%", "rating": "A" }, { "name": "Gross Margin", "value": "66.16%", "rating": "A" }, { "name": "Revenue YoY", "value": "15.81%", "rating": "B" }, { "name": "Net Profit YoY", "value": "45.44%", "rating": "B" }, { "name": "Total Assets YoY", "value": "2.59%", "rating": "C" }, { "name": "Net Assets YoY", "value": "5.62%", "rating": "C" }, { "name": "Cash Flow Margin", "value": "0.00%", "rating": "D" }, { "name": "OCF YoY", "value": "15.81%", "rating": "B" }, { "name": "Turnover", "value": "0.26", "rating": "D" }, { "name": "Gearing Ratio", "value": "5.77%", "rating": "A" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | 35.05 | 21/64 | 43.58 | 39.51 | 36.87 | | PB | 3.32 | 39/64 | 3.35 | 3.00 | 2.72 | | PS (TTM) | 12.34 | 54/64 | 12.76 | 11.51 | 10.64 | | Dividend Yield | 1.31% | 21/64 | 1.75% | 1.56% | 1.39% | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | APT (688617.SH) | A | B | B | A | B | A | | 02 | United Imaging Healthcare (688271.SH) | B | A | C | B | B | B | | 03 | iRay (688301.SH) | B | A | D | C | A | B | | 04 | YUYUE MEDICAL (002223.SZ) | B | C | C | A | C | B | | 05 | Insight Lifetech (688712.SH) | B | A | E | A | A | B | ## Institutional View ### Analyst Rating Distribution > As of 2026-04-28T16:00:00.000Z Total Analysts: **2** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 2 | 100% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 60.91 | | Highest Target | 72.00 | | Lowest Target | 72.00 | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688580.SH/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688580.SH/norm.md) - [Related News](https://longbridge.com/en/quote/688580.SH/news.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**